Table 1.

Summary of IgAN cases in haematological malignancy patients

Paper	Gender	Age (years)	Location	IgAN timing relative to malignancy Sx	Malignancy	Stage	SCr	Proteinuria	Haematuria	Serum IgA level	Kidney biopsy	Malignancy treatment	Renal recovery post malignancy treatment
Motoyama 2008 [10]	F	5	JPN	5 years post	ALL (undifferentiated)	NA	Normal	Present	Macro	Elevated	Crescents, mesangial proliferation, mesangial IgA deposits	Prednisolone, vincristine, methotrexate, 6-MP	No – recurrent microhaematuria w/o persistent proteinuria
Iwata 2006 [18]	M	28	JPN	8 years prior	ALL (undifferentiated)	NA	53 μmol/L	3 g/day	Micro	Normal	Glomerulosclerosis, mild mesangial proliferation, mesangial IgA deposits	Prednisolone, vincristine, daunorubicine, etoposide, mitoxantrone, cytarabine, methotrexate, peripheral stem cell transplantation	Yes – proteinuria decreased to 0.5 g/day at 16 months post CTx
Bergmann 2005 [9]	F	60	DEU	4 weeks post	Hodgkin lymphoma (mixed cellularity)	IIIA	681 μmol/L	2.3 g/day	Micro	Elevated	Crescents, diffuse mesangial proliferation, mesangial IgA deposits	Prednisolone, cyclophosphamide, etoposide, bleomycin, doxorubicin, vincristine, procarbazine	Yes – SCr, proteinuria within normal range
Khositseth 2007 [16]	M	14	THA	6 months post	Hodgkin lymphoma (nodular sclerosing)	IIIE	80 μmol/L	0.8 g/day	Micro	NR	Glomerulosclerosis, diffuse mesangial proliferation, mesangial IgA deposits	Cyclophosphamide, vincristine, doxorubicin, prednisolone	Yes – proteinuria normalized, urine RBC < 50/HPF
Cherubini 2001 [15]	M	44	ITA	1 year post	Hodgkin lymphoma (nodular sclerosing)	IV	354 μmol/L	4 g/day	Micro	Elevated	Crescents, mesangial IgA deposits	Prednisolone, nitrogen mustards, oncovin, procarbazine, adriamycin, bleomycin, vinblastine, dacarbazine	Yes – SCr within normal limits
Harada 2017 [11]	M	79	JPN	Same	Angioimmunoblastic T-cell lymphoma	IV	159 μmol/L	1.5 g/day	Micro	Elevated	Mesangial IgA deposits, lymphoma invasion	Prednisolone, cyclophosphamide, pirarubicine, vincristine	Yes – SCr, proteinuria, haematuria within normal range
Moe 1993 [13]	F	66	USA	6 months post	Mycosis fungoides	IV	High	1.0 g/day	Macro	NR	Crescents, diffuse mesangial proliferation, mesangial IgA deposits	Psoralen-ultraviolet A, allopurinol	No-IgAN presented after failed treatment
Ramirez 1981 [14]	M	70	USA	1 year post	Mycosis fungoides	IV	177 μmol/L	NR	Micro	NR	Glomerulosclerosis, mesangial proliferation, mesangial IgA deposits	NR	NR
Ramirez 1981 [14]	M	56	USA	3 years post	Mycosis fungoides	IV	Normal	NR	Micro	NR	Focal mesangial proliferation, mesangial IgA deposits	NR	NR
Motoyama 2008 [10]	M	12	JPN	3 years prior	Diffuse medium-sized B cell lymphoma	II	Normal	NR	Micro	Normal	Mild mesangial proliferation, mesangial IgA deposits	Prednisolone, cyclophosphamide, epirubicine, methotrexate, etoposide, cytarabine	No-recurrent macrohaematuria w/o persistent proteinuria
Mak 1998 [17]	M	62	HKG	Same	MALT B-cell lymphoma	IV	309 μmol/L	4.1 g/day	Macro	Elevated	Glomerulosclerosis, diffuse mesangial proliferation, mesangial IgA deposits, lymphoma invasion	Chlorambucil	Yes – SCr, proteinuria, haematuria within normal limits
Forslund 2007 [19]	M	76	FIN	5 years post	Multiple myeloma	III	752 μmol/L	4.0 g/day	Micro	Low	Mesangial proliferation, mesangial IgA deposits	Prednisolone, vincristine, cyclophosphamide, melphalan, adriamycin, dexamethasone, thalidomide, bortezomib	Yes – SCr 168 μmol/L 1 month post-treatment

Abbreviations: 6-MP 6-mercaptopurine, ALL acute lymphoblastic leukaemia, CTx chemotherapy, DEU Germany, dx diagnosis, F female, FIN Finland, HKG Hong Kong, HPF high power field, IgA immunoglobulin A, IgAN immunoglobulin A nephropathy, JPN Japan, M male, Micro microhaematuria, Macro macrohaematuria, NA not applicable, NR not reported, RBC red blood cells, SCr serum creatinine, Sx symptoms, THA Thailand, USA United States of America, w/o without

Staging methods: Hodgkin lymphoma: Ann Arbor staging system, Non-Hodgkin lymphoma: Ann Arbor staging system, Mycosis fungoides: Tumour Node Metastasis system, Multiple myeloma: Durie-Salmon system